ESEN

Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial - The American Journal of Managed Care

Comentar en el chat
1fuente
1país
1idioma
13:20detectada el 16/11 (19:20 UTC)
13:20última novedad, 16/11
1noticia

Cadena de publicación

La publicó primero The American Journal of Managed Care (Malasia) el 16/11 a las 13:20 (19:20 UTC).

  1. 13:2016/11, 19:20 UTC
    AJThe American Journal of Managed Care news.google.com MY EN Primera
    Ribupatide Yields Up to 17.7% Weight Loss in Phase 3 GEMINI-1 Trial - The American Journal of Managed Care

Datos de esta historia: JSON